Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1

4 trials 2 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

1 Sponsors

6 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 2 Phase II: 1 Phase I (Other): 1

Indications tested

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency 4 Pseudoxanthoma elasticum 1

Sponsors using this IMP

Inozyme Pharma Inc. 4

All trials

4 total

The ENERGY 2 Study: A study to investigate if study drug INZ-701 increases survival in infants with ENPP1 Deficiency by preventing heart dys… Recruiting

2024-512991-36-00 Phase III 5 countries Inozyme Pharma Inc.
A Long-term Follow-up Study of Participants who Received INZ-701 in a previous clinical study Recruiting

2024-512715-42-00 Phase II 2 countries Inozyme Pharma Inc.
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency Ended

2023-507382-26-00 Phase III 2 countries Inozyme Pharma Inc.
The ENERGY Study: Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants with ENPP1 Deficiency… Ended

2023-507384-20-00 Phase I (Other) 1 country Inozyme Pharma Inc.

Showing 1–4 of 4 trials

← All drugs A–Z